<DOC>
	<DOCNO>NCT01147510</DOCNO>
	<brief_summary>To compare efficacy combination therapy montelukast plus low dose inhale budesonide single therapy medium dose inhale budesonide asthma control inflammatory marker clinical indicator compare treatment response accord leukotriene related genotype elderly patient asthma</brief_summary>
	<brief_title>Asthma Control Elderly Patients With Montelukast</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Patients age 60 75 year Patients diagnose asthma ( NIH , 2007 ) six month ago Patients maintain monotherapy low dose inhale budesonide ( pulmicort 400µg/day ciclesonide 160 µg/day fluticasone 250 µg/day ) combination low dose inhale budesonide LABA ( Seretide® 250 µg/day Symbicort® 320 µg/day ) month participation trial Patients reach 'well control asthma status ' fourweek monotherapy low dose inhale budesonide ( Pulmicort 400 µg/day ) Patients sufficiently listen purpose content trial property investigational product voluntarily agree participation sign write consent approve IRB Ajou University Medical Center participation trial Patients show symptom acute disease within 28 day begin trial ( administration trial medication ) Volunteers find unsuitable screening test Patients history hypersensitivity montelukast budesonide Patients participate clinical trial within three month begin trial ( administration trial medication ) current smoker 10PYs smoke history Patients need administration medication affect asthma control systemic immunoregulatory drug ( cyclosporin , omalizumab , etc . ) due disease except asthma</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>asthma control elderly patient</keyword>
	<keyword>age 60-75</keyword>
</DOC>